^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    2d
    ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (clinicaltrials.gov)
    P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    VASCATAQ: VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P4, N=13, Completed, University Hospital, Rouen | Recruiting --> Completed | N=40 --> 13
    Trial completion • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation
    |
    Avastin (bevacizumab)
    2d
    Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, Washington University School of Medicine
    New P1/2 trial
    |
    IDH wild-type
    |
    tovecimig (CTX-009)
    3d
    Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab)
    3d
    ESM1 SUMOylation mediates bevacizumab resistance in ovarian cancer through ITGB1-FAK-driven angiogenesis. (PubMed, Cell Rep)
    In OC mice, TRIM28 overexpression promotes angiogenesis and Bev resistance via ESM1-mediated ITGB1/FAK activation. This work unveils a new molecular pathway underlying Bev resistance in OC and proposes TRIM28 and ESM1 as potential therapeutic targets.
    Journal
    |
    ITGB1 (Integrin Subunit Beta 1) • TRIM28 (Tripartite Motif Containing 28) • ESM1 (Endothelial Cell Specific Molecule 1)
    |
    Avastin (bevacizumab)
    3d
    The Eylea 8mg Switch Study (clinicaltrials.gov)
    P=N/A, N=50, Active, not recruiting, Vienna Institute for Research in Ocular Surgery
    New trial
    |
    Eylea (aflibercept intravitreal)
    3d
    NISTIPS: NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy (clinicaltrials.gov)
    P=N/A, N=350, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (clinicaltrials.gov)
    P3, N=443, Completed, Jecho Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    Lucentis (ranibizumab)
    3d
    Kirros: A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis (clinicaltrials.gov)
    P2, N=30, Recruiting, Genentech, Inc. | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    4d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    5d
    Comparison of Different Maintenance Treatment Options for Newly Diagnosed BRCAwt Advanced Ovarian Cancer: A Retrospective Cohort Analysis. (PubMed, Technol Cancer Res Treat)
    In the PSM sensitivity analysis, the median PFS was not reached (95% CI, 19.55-NR) in the niraparib group and was 18.33 months (95% CI, 8.90-25.26) in the bevacizumab group (HR = 0.360, 95% CI, 0.176-0.736; P = .005).ConclusionThis analysis suggests that niraparib may provide a progression-free survival advantage compared with bevacizumab in BRCAwt AOC patients, with both regimens appearing to be generally well tolerated in the real-world setting. These findings offer preliminary reference value for maintenance treatment selection in patients with newly diagnosed BRCAwt AOC.
    Clinical • Retrospective data • Journal
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type
    |
    Avastin (bevacizumab) • Zejula (niraparib)
    5d
    Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity. (PubMed, JHEP Rep)
    We identified EM to represent a common event in patients with HCC after treatment initiation and demonstrated impaired liver function, elevated biomarkers of inflammation, and reduced lymphocyte frequencies and increased regulatory T cell activity to be associated with increased EM risk. These findings can help clinicians identify patients with HCC at high risk of EM, enabling adequate and informed decision-making regarding end-of-life care and palliative treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD44 (CD44 Molecule) • CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)